<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3247">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04438057</url>
  </required_header>
  <id_info>
    <org_study_id>MIDC-CCP</org_study_id>
    <nct_id>NCT04438057</nct_id>
  </id_info>
  <brief_title>Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19</brief_title>
  <official_title>Evaluating the Efficacy of Convalescent Plasma in Symptomatic Outpatients Infected With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Metro Infectious Disease Consultants</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Metro Infectious Disease Consultants</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will provide investigational convalescent plasma for patients infected with the&#xD;
      SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician&#xD;
      evaluation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will provide investigational convalescent plasma for patients infected with the&#xD;
      SARS-CoV-2 with mild to moderate symptoms who meet inclusion criteria as judged by physician&#xD;
      evaluation.&#xD;
&#xD;
      Following patient enrollment into the study, completion of informed consent and&#xD;
      randomization, the patient will receive one unit of convalescent COVID plasma or standard of&#xD;
      care. The plasma will be infused in an outpatient infusion center by highly trained and&#xD;
      experienced staff. Vitalant will be providing the plasma as per their normal screening and&#xD;
      distribution protocols. Patients will be monitored for safety during the infusion and per&#xD;
      protocol following the infusion for a period of 28 days. Primary efficacy and safety&#xD;
      endpoints will be statistically analyzed and compared between the two groups.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 12, 2020</start_date>
  <completion_date type="Anticipated">August 12, 2021</completion_date>
  <primary_completion_date type="Actual">August 12, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Outpatient open label randomized study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time to Resolution of Symptoms</measure>
    <time_frame>28 days</time_frame>
    <description>a. Time to resolution of symptoms will be defined as time from randomization (day 0) to a successful outcome. c. A successful outcome is defined as symptom improvement of 3 numbers or down to zero on the memory aid for all symptoms noted.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>SAEs within 24 hours of plasma infusion</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in Inflammatory Markers</measure>
    <time_frame>28 days</time_frame>
    <description>A 50% decrease at day 28 in C-Reactive Protein (mg/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Inflammatory Markers</measure>
    <time_frame>28 days</time_frame>
    <description>A 50% decrease at day 28 in D-Dimer (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Inflammatory Markers</measure>
    <time_frame>28 days</time_frame>
    <description>A 50% decrease at day 28 in Ferritin (ng/mL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in Inflammatory Markers</measure>
    <time_frame>28 days</time_frame>
    <description>A 50% decrease at day 28 in Lactate Dehydrogenase (U/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization within 28 days</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patient will receive standard of care therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will receive convalescent plasma</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CCP</intervention_name>
    <description>Randomized open label study to receive 2:1 CCP to standard of care</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <other_name>convalescent plasma</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory confirmed diagnosis of infection with SARS-CoV-2&#xD;
&#xD;
          -  Symptoms of COVID -19 - cough, fever, sore throat, SOB, anosmia, diarrhea, myalgia&#xD;
&#xD;
          -  Symptoms less than 14 days&#xD;
&#xD;
          -  ID Physician determination that the patient does not need hospitalization&#xD;
&#xD;
          -  O2 saturation of &gt;93%&#xD;
&#xD;
          -  Informed consent provided by the patient or healthcare proxy&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Ambulatory Outpatient when informed consent obtained and study drug is administered&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 18 y/o&#xD;
&#xD;
          -  Patients currently receiving intravenous immunoglobulin&#xD;
&#xD;
          -  Hypercoagulable state - neoplasia, Collagen vascular disease, Myelodysplastic&#xD;
             syndrome, chronic anticoagulation treatment, etc.&#xD;
&#xD;
          -  Need to be hospitalized&#xD;
&#xD;
          -  O2 sat &lt; 93%&#xD;
&#xD;
          -  D-Dimer &gt; 2x normal&#xD;
&#xD;
          -  Chronic oxygen therapy&#xD;
&#xD;
          -  Renal insufficiency with Creatinine clearance &lt; 30&#xD;
&#xD;
          -  Long term care or assisted living facility resident&#xD;
&#xD;
          -  Ongoing usage of hydroxychloroquine for any indication&#xD;
&#xD;
          -  History of blood or plasma transfusion related complications&#xD;
&#xD;
          -  Enrollment into any other investigational drug or device study within the previous 30&#xD;
             days&#xD;
&#xD;
          -  Any drug, chemical or alcohol dependency as determined by the investigator through&#xD;
             history that may affect study procedures and follow up&#xD;
&#xD;
          -  Pregnant or breast feeding&#xD;
&#xD;
          -  Any acute or chronic medical comorbidity, psychiatric, social or other circumstance&#xD;
             that, in the opinion of the investigator, may interfere with study compliance,&#xD;
             completion, or accurate assessment of the study outcomes/safety&#xD;
&#xD;
          -  Admitted to or expected to be admitted to a medical facility&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Metro Infectious Disease Consultants</name>
      <address>
        <city>Burr Ridge</city>
        <state>Illinois</state>
        <zip>60527</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicholas Van Hise, PharmD</last_name>
      <phone>630-655-6952</phone>
      <email>nvanhise@midcusa.com</email>
    </contact>
    <contact_backup>
      <last_name>Nathan Skorodin, PharmD</last_name>
      <email>nskorodin@midcusa.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 17, 2020</study_first_submitted>
  <study_first_submitted_qc>June 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2020</study_first_posted>
  <last_update_submitted>August 19, 2020</last_update_submitted>
  <last_update_submitted_qc>August 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>convalescent plasma</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

